托马斯·施尼克纳
Thomas Schinecker
领导Switzerland大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导Switzerland大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in Switzerland
最新观点
-
2026年上半年保持强劲势头,恒定汇率下销售额增长6%,管线取得积极进展,FDA授予五项优先审评
Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development. We reported positive phase III data for divarasib, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews.
-
晚期管线项目充足,到2030年最多可能有19款药物上市,因此公司并不像部分同行那样面临追加并购的压力
I think we're well set up for growth into the next decade. In fact, our late-stage pipeline is so full that adding something late stage, we would then have to see how to reallocate more money into these programs. Currently, Roche is pushing several medicines through the pipeline, with up to 19 potentially launching by 2030.